ROTH Capital Partners

Etsy Inc (NASDAQ: ETSY) announced 23.6 percent year-over-year revenue growth and a 17.8-percent increase in gross merchandise sales, or GMS, to $1.02 billion in its fourth-quarter report Tuesday. The Analyst Roth Capital Partners analyst Darren Aftahi upgraded his rating on the shares of...

Salesforce.com, inc. (NYSE: CRM) reported 25 percent revenue growth and 26 percent billings growth for the fiscal third quarter on Tuesday. The bottom line came in ahead of the consensus estimate. The company's fourth quarter non-GAAP earnings per share guidance trailed Street forecasts,...

Solar stocks are volatile investments, as they carry a high level of headline risk. Shares of Canadian Solar Inc. (NASDAQ: CSIQ) tanked Thursday after the company released its fiscal third quarter results. One analyst is upbeat about the company's prospects due to an anticipated business...

Shares of Galectin Therapeutics Inc (NASDAQ: GALT), a clinical-stage biopharmaceutical company that creates therapies for fibrotic disease and cancer, tumbled nearly 50 percent on Wednesday after the company said that a Phase 2a study called NASH-FX involving its GR-MD-02 therapy failed its...

Roth Capital has upgraded Aptose Biosciences Inc (NASDAQ: APTO) to Buy from Neutral "on an expected inflection point in the near-term, namely the allowance for APTO-253 to return to the clinical." Belonging to a new small molecules class, APTO-253 "is designed to induce a silent tumor-suppressive...

Roth Capital Partners analyst Chris Lewis has downgraded EnteroMedics Inc (NASDAQ: ETRM) shares to a Neutral rating from Buy citing lack of reimbursement limits and commercial adoption or utilization growth. The firm has a 12-month price target of $0.50 on the stock. The analyst said, "While we...

“Heading into H2’16, we are cautious on our entire group of upstream manufacturers given the threat of overcapacity in Q3 as demand in China weakens,” ROTH Capital’s Philip Shen stated. Shen downgraded the rating on Trina Solar Limited (ADR) (NYSE: TSL) to Neutral, while...

JinkoSolar Holding Co., Ltd. (NYSE: JKS) reported its Q1 results ahead of expectations, while issuing a robust Q2 guidance. ROTH Capital’s Philip Shen maintained a Buy rating on the company, while lowering the price target from $30 to $35. “Heading into H2’16, we are...

Roth Capital’s Krishna Shankar mentioned recent industry data points suggest iPhone 7 shipments of 70–75 million in 2H16, with InvenSense Inc (NYSE: INVN) expected to continue to be a major supplier for Apple Inc. (NASDAQ: AAPL). Shankar maintains a Buy rating on InvenSense, with a...

Fibrocell Science Inc (NASDAQ: FCSC) is leveraging its expertise with fibroblasts to target monogenic diseases as well as broader indications. Roth Capital Partners’ Joseph Pantginis resumed coverage of the company with a Buy rating and a $7 price target. Fibrocell plans using gene...

ReneSola Ltd. (ADR) (NYSE: SOL) reported its Q1 results ahead of expectations, while guiding to a better-than-anticipated Q2. Roth Capital’s Philip Shen reiterated a Neutral rating on the company, with a price target of $1.45. 1Q Results ReneSola reported a modest revenue beat for the quarter...

Unfortunately, the rise in crude oil prices in 2016 is too little too late for a number of oil and gas E&Ps. However, according to Roth Capital Partners analyst John White, there are still plenty of E&P buying opportunities out there. “We don’t like writing about this any more...